PFS

2:21
Combatting oral mucositis with cryotherapy after high dose melphalan
Monika Engelhardt
2:25
Myeloma XI update: vorinostat/lenalidomide not a winning combination for maintenance
Matthew Jenner
1:04
Revolutionizing MM treatment with daratumumab
Matthew Jenner
1:07
Ibrutinib treatment for CLL yields different PFS in population-based setting
Lina van der Straten
2:00
Haploidentical vs. unrelated transplants in DLBCL
Anna Sureda
0:58
Ibrutinib for CLL within a population-based setting: a promising outlook
Lina van der Straten
4:29
Multiple Myeloma trial highlights: ARROW, OPTIMISMM & ALCYONE
Mohamad Mohty
1:29
Stem cell therapies promising for Hodgkin lymphoma
Anna Sureda
2:18
Novel drug combinations for Hodgkin lymphoma: more effective & less toxic
Anna Sureda
1:25
Lenalidomide maintenance remains best for newly diagnosed MM
Francesca Gay
3:08
Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel
2:06
Improving the cure rate of multiple myeloma
Niels van de Donk
1:21
ENDEAVOUR: carfilzomib/dexamethasone therapy for relapsed MM
Rakesh Popat
1:41
CAR T-cells in myeloma: are they as promising as we think?
Faith Davies
1:44
Improved survival in MM with thalidomide before and after ASCT
Niels van de Donk
1:56
Randomized trials of pomalidomide combinations for MM
Meletios Dimopoulos
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals